<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00176059</url>
  </required_header>
  <id_info>
    <org_study_id>NTx-Ig-003</org_study_id>
    <nct_id>NCT00176059</nct_id>
  </id_info>
  <brief_title>Immunoregulatory Effects of Immunoglobulin Induction Therapy in Renal Transplant Recipients</brief_title>
  <official_title>Immunoglobulin Induction Therapy in Renal Transplant Recipients on Tacrolimus/Azathioprine or Tacrolimus/MMF: Effects on Th1, Th2, B Cell-/Monokine Responses and Immunoregulatory Autoantibody Levels</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Giessen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Heidelberg University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Astellas Pharma Inc</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Aventis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Giessen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this randomized prospective study in renal transplant recipients is to investigate
      immunological short and long-term effects of an IVIG induction therapy.

      Furthermore clinical endpoints (patient and graft survival, incidence of acute and chronic
      rejection, infectious diseases and graft function) up to three years posttransplant will be
      analyzed.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Intravenous immunoglobulin (IVIG) preparations are known to be effective in the treatment of
      various autoimmune and inflammatory disorders due to their immunomodulatory and
      antiinflammatory properties. It has been demonstrated that IVIG is effective in the treatment
      of acute vascular rejection and steroid resistant cellular rejection. Furthermore, IVIG has
      been used to inhibit production of lymphocytotoxic antibodies in highly sensitized patients
      so that successful cadaveric or living renal transplantation could be performed.

      The aim of this randomized prospective study in renal transplant recipients is to investigate
      immunological short and long-term effects of an IVIG induction therapy on Th1, Th2 and
      B-cell/monocyte responses, expression of adhesion molecules, costimulatory factors and
      cytokine receptors and on secretion of immunoregulatory autoantibodies (anti-F(ab)-,
      anti-F(ab')2G-, anti-hinge autoantibodies). These autoantibodies have been shown to
      significantly affect the risk of chronic rejection and graft loss.

      Furthermore, clinical endpoints (patient and gaft survival, incidence of acute and chronic
      rejection, infectious diseases and graft function) up to 3 years will be analyzed.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2001</start_date>
  <completion_date type="Actual">May 2006</completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>patient survival</measure>
    <time_frame>1 year / 3 years / 5 years posttransplant</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>graft survival</measure>
    <time_frame>1 year / 3 years / 5 years posttransplant</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>acute rejection</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>chronic allograft nephropathy</measure>
    <time_frame>3 years / 5 years posttransplant</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>graft function</measure>
    <time_frame>1 year / 3 years / 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>infectious complications</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>immunoglobulin levels</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>regulatory autoantibody levels</measure>
    <time_frame>1 year / 3 years / 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Th1 and Th2 responses</measure>
    <time_frame>1 year / 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>B-cell/monocyte responses</measure>
    <time_frame>1 year / 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Expression of adhesion molecules, costimulatory molecules and cytokine receptors</measure>
    <time_frame>1 year / 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>proteinuria (quantitative assessment)</measure>
    <time_frame>1 year / 3 years</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">50</enrollment>
  <condition>Renal Failure, Chronic</condition>
  <condition>Renal Transplantation</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>intravenous immunoglobulins (IVIG)</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>kidney transplantation</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  renal transplant recipients of the Giessen renal transplant unit

          -  cadaveric and living renal transplants

          -  first and retransplants

        Exclusion Criteria:

          -  Contraindications against blood-taking (anaemia with hemoglobin &lt; 9,5 g/l,
             hypotension)

          -  intravenous immunoglobulin therapy in the last half year before study entry

          -  Hyperimmunoglobulin therapy for severe CMV infection

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rolf Weimer, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Internal Medicine, University of Giessen, Giessen, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Internal Medicine, University of Giessen</name>
      <address>
        <city>Giessen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Weimer R, Süsal C, Yildiz S, Streller S, Pelzl S, Staak A, Renner F, Dietrich H, Daniel V, Feuring E, Kamali-Ernst S, Ernst W, Padberg W, Opelz G. sCD30 and neopterin as risk factors of chronic renal transplant rejection: impact of cyclosporine A, tacrolimus, and mycophenolate mofetil. Transplant Proc. 2005 May;37(4):1776-8.</citation>
    <PMID>15919463</PMID>
  </reference>
  <reference>
    <citation>Weimer R, Zipperle S, Daniel V, Carl S, Staehler G, Opelz G. Superior 3-year kidney graft function in patients with impaired pretransplant Th2 responses. Transpl Int. 1998;11 Suppl 1:S350-6.</citation>
    <PMID>9665014</PMID>
  </reference>
  <reference>
    <citation>Weimer R, Zipperle S, Daniel V, Carl S, Staehler G, Opelz G. Pretransplant CD4 helper function and interleukin 10 response predict risk of acute kidney graft rejection. Transplantation. 1996 Dec 15;62(11):1606-14.</citation>
    <PMID>8970616</PMID>
  </reference>
  <reference>
    <citation>Süsal C, Döhler B, Opelz G. Graft-protective role of high pretransplantation IgA-anti-Fab autoantibodies: confirmatory evidence obtained in more than 4000 kidney transplants. The Collaborative Transplant Study. Transplantation. 2000 Apr 15;69(7):1337-40.</citation>
    <PMID>10798750</PMID>
  </reference>
  <reference>
    <citation>Süsal C, Dörr C, Groth J, May G, Opelz G. Pretransplant serum IgA concentration and IgA-anti-Fab autoantibody activity as prognostic indicators of kidney graft survival. Transpl Int. 1994;7 Suppl 1:S586-9.</citation>
    <PMID>11271315</PMID>
  </reference>
  <reference>
    <citation>Süsal C, Wiesel M, Staehler G, Groth J, May G, Opelz G. Excellent kidney graft survival in patients with high pretransplant serum IgA concentrations and IgA-anti-Fab autoantibody activity. Transplant Proc. 1995 Feb;27(1):1072-4.</citation>
    <PMID>7878810</PMID>
  </reference>
  <reference>
    <citation>Süsal C, Guo ZG, Terness P, Opelz G. Role of anti-IgG autoantibodies in kidney transplantation. Immunol Lett. 1990 Nov;26(2):121-5.</citation>
    <PMID>2269482</PMID>
  </reference>
  <reference>
    <citation>Süsal C, Wiesel M, Schönemann C, Groth J, Carl S, Staehler G, May G, Opelz G. Presensitization and HLA match influence the predictive power of pretransplant serum IgA and IgA-anti-Fab autoantibodies in kidney graft recipients. Transplant Proc. 1997 Feb-Mar;29(1-2):1444-6.</citation>
    <PMID>9123373</PMID>
  </reference>
  <reference>
    <citation>Sùsal C, Kröpelin M, Groth J, Wiesel M, May G, Carl S, Staehler G, Opelz G. Protective effect of autoantibodies against the hinge region of human IgG in kidney graft recipients. Transplantation. 1996 Nov 27;62(10):1534-6.</citation>
    <PMID>8958291</PMID>
  </reference>
  <reference>
    <citation>Süsal C, Kröpelin M, Wiesel M, Staehler G, Groth J, May G, Opelz G. Pretransplant IgA-anti-hinge and IgA-anti-Fab autoantibody activity is associated with good kidney graft survival. Transplant Proc. 1995 Oct;27(5):2663-5.</citation>
    <PMID>7482869</PMID>
  </reference>
  <reference>
    <citation>Terness PI, Navolan D, Dufter C, Welschof M, Opelz G. Immunosuppressive anti-immunoglobulin autoantibodies: specificity, gene structure and function in health and disease. Cell Mol Biol (Noisy-le-grand). 2002 May;48(3):271-8. Review.</citation>
    <PMID>12030431</PMID>
  </reference>
  <reference>
    <citation>Terness P, Navolan D, Kohl I, Siedler F, Moroder L, Dufter C, Welschof M, Schneider F, Drugarin D, Opelz G. Role of idiotype-independent anti-IgG autoantibodies in human kidney transplantation: natural anti-F(ab')2 antibodies recognize an IgG1 hinge region epitope. Transplant Proc. 1997 Feb-Mar;29(1-2):1412-4.</citation>
    <PMID>9123359</PMID>
  </reference>
  <reference>
    <citation>Terness P, Navolan D, Moroder L, Siedler F, Weyher E, Kohl I, Dufter C, Welschof M, Drugarin D, Schneider F, Opelz G. A natural IgA-anti-F(ab')2gamma autoantibody occurring in healthy individuals and kidney graft recipients recognizes an IgG1 hinge region epitope. J Immunol. 1996 Nov 1;157(9):4251-7.</citation>
    <PMID>8892664</PMID>
  </reference>
  <reference>
    <citation>Tyan DB, Li VA, Czer L, Trento A, Jordan SC. Intravenous immunoglobulin suppression of HLA alloantibody in highly sensitized transplant candidates and transplantation with a histoincompatible organ. Transplantation. 1994 Feb 27;57(4):553-62.</citation>
    <PMID>8116041</PMID>
  </reference>
  <reference>
    <citation>Weimer R, Schweighoffer T, Schimpf K, Opelz G. Helper and suppressor T-cell function in HIV-infected hemophilia patients. Blood. 1989 Jul;74(1):298-302.</citation>
    <PMID>2568859</PMID>
  </reference>
  <reference>
    <citation>Weimer R, Daniel V, Zimmermann R, Schimpf K, Opelz G. Autoantibodies against CD4 cells are associated with CD4 helper defects in human immunodeficiency virus-infected patients. Blood. 1991 Jan 1;77(1):133-40.</citation>
    <PMID>1824617</PMID>
  </reference>
  <results_reference>
    <citation>Staak A, Renner F, Suesal C, Dietrich H, Rainer L, Kamali-Ernst S, Ernst W, Padberg W, Opelz G, Weimer R. Immunoglobulin induction therapy in renal transplant recipients: Effects on immunoglobulin and regulatory antibody levels. Transplant Proc. 2006 Dec;38(10):3483-5.</citation>
    <PMID>17175311</PMID>
  </results_reference>
  <verification_date>May 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 9, 2005</study_first_submitted>
  <study_first_submitted_qc>September 9, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 15, 2005</study_first_posted>
  <last_update_submitted>May 8, 2007</last_update_submitted>
  <last_update_submitted_qc>May 8, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 10, 2007</last_update_posted>
  <keyword>immunoglobulins, intravenous</keyword>
  <keyword>kidney transplantation</keyword>
  <keyword>acute rejection</keyword>
  <keyword>chronic rejection</keyword>
  <keyword>regulatory autoantibodies</keyword>
  <keyword>Th1</keyword>
  <keyword>Th2</keyword>
  <keyword>B Cell</keyword>
  <keyword>Monokines</keyword>
  <keyword>Cytokine promoter gene polymorphisms</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins, Intravenous</mesh_term>
    <mesh_term>gamma-Globulins</mesh_term>
    <mesh_term>Rho(D) Immune Globulin</mesh_term>
    <mesh_term>Autoantibodies</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

